Loading...
Aquestive Therapeutics, Inc.
AQST•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$4.15
$-0.05(-1.19%)
Aquestive Therapeutics, Inc. (AQST) Financial Performance & Income Statement Overview
Review Aquestive Therapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
13.80%
↑ 13.80%
Operating Income Growth
-103.75%
↓ 103.75%
Net Income Growth
-460.83%
↓ 460.83%
Operating Cash Flow Growth
-460.49%
↓ 460.49%
Operating Margin
-75.94%
↓ 75.94%
Gross Margin
68.40%
↑ 68.40%
Net Profit Margin
-100.02%
↓ 100.02%
ROE
107.41%
↑ 107.41%
ROIC
-49.06%
↓ 49.06%
Aquestive Therapeutics, Inc. (AQST) Income Statement & Financial Overview
Review Aquestive Therapeutics, Inc.'s (AQST) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $11.87M | $13.54M | $20.10M | $12.05M |
| Cost of Revenue | $4.52M | $4.44M | $4.53M | $4.39M |
| Gross Profit | $7.35M | $9.11M | $15.57M | $7.66M |
| Gross Profit Ratio | $0.62 | $0.67 | $0.77 | $0.64 |
| R&D Expenses | $4.92M | $5.27M | $4.16M | $5.93M |
| SG&A Expenses | $16.009M | $12.13M | $11.36M | $10.69M |
| Operating Expenses | $20.93M | $17.39M | $15.52M | $16.62M |
| Total Costs & Expenses | $25.45M | $21.83M | $20.04M | $21.01M |
| Interest Income | $734000.00 | $979000.00 | $1.40M | $329000.00 |
| Interest Expense | $4.22M | $4.20M | $4.20M | $4.20M |
| Depreciation & Amortization | $147000.00 | $159000.00 | $205000.00 | $207000.00 |
| EBITDA | -$12.70M | -$7.15M | $260000.00 | -$8.42M |
| EBITDA Ratio | -$1.07 | -$0.53 | $0.01 | -$0.70 |
| Operating Income | -$13.58M | -$8.29M | $55000.00 | -$8.96M |
| Operating Income Ratio | -$1.14 | -$0.61 | $0.003 | -$0.74 |
| Other Income/Expenses (Net) | -$3.49M | -$3.22M | -$2.80M | -$3.87M |
| Income Before Tax | -$17.07M | -$11.51M | -$2.75M | -$12.83M |
| Income Before Tax Ratio | -$1.44 | -$0.85 | -$0.14 | -$1.06 |
| Income Tax Expense | -$14000.00 | $0.00 | $0.00 | $163724.00 |
| Net Income | -$17.05M | -$11.51M | -$2.75M | -$12.83M |
| Net Income Ratio | -$1.44 | -$0.85 | -$0.14 | -$1.06 |
| EPS | -$0.19 | -$0.13 | -$0.03 | -$0.17 |
| Diluted EPS | -$0.19 | -$0.13 | -$0.03 | -$0.17 |
| Weighted Avg Shares Outstanding | $91.20M | $91.08M | $90.91M | $73.61M |
| Weighted Avg Shares Outstanding (Diluted) | $91.20M | $91.08M | $90.91M | $73.61M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan